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An active lifestyle is crucial to maintain health into old age; inversely, sedentariness 
has been linked to an elevated risk for many chronic diseases. The discovery of 
myokines, hormones produced by skeletal muscle tissue, suggests the possibility that 
these might be molecular mediators of the whole body effects of exercise originating 
from contracting muscle fibers. Even though less is known about the sedentary state, 
the lack of contraction-induced myokines or the production of a distinct set of 
hormones in the inactive muscle could likewise contribute to pathological 
consequences in this context. In this review, we try to summarize the most recent 
developments in the study of muscle as an endocrine organ and speculate about the 







- Besides its traditional functions, skeletal muscle has recently been discovered to be 
an endocrine organ 
- Myokines are signaling molecules with auto-, para- and/or endocrine functions that 
are secreted from skeletal muscle cells 
- Myokines affect most organs and thereby provide a molecular explanation for the 










AMPK   AMP-dependent kinase 
AP-1  Activator protein 1 
aP2   Adipocyte protein 2 
BAIBA  β-Aminoisobutyric acid 
BAT   Brown adipose tissue 
BDNF   Brain-derived neurotrophic factor 
CaMK  Calcium/calmodulin-dependent protein kinase 
C/EBPα  CCAAT-enhancer-binding protein α 
CnA  Calcineurin A 
CNTF   Ciliary neurotrophic factor 
CREB   Cyclic-AMP-responsive-element-binding protein 
CXCR2  CXC receptor 2 
ERRα  Estrogen-related receptor α 
FGF21  Fibroblast growth factor 21 
GLP-1   Glucagon-like peptide-1 
GLUT4  Glucose transporter 4 
HIF-1α  Hypoxia inducible factor 1α 
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IGF-1   Insulin-like growth factor 1 
IL   Interleukin 
JAK   Janus kinase 
MEF   Myocyte-enhancer factor 
Metrnl   Meteorin-like 
MSTN   Myostatin 
NFAT   Nuclear factor of activated T cells 
NFκB  Nuclear factor κB 
NRF-1  Nuclear respiratory factor 1 
OSM   Oncostatin-M 
p38 MAPK  p38 mitogen-activated protein kinase 
PGC-1α  Peroxisome-proliferator activated receptor γ coactivator 1α 
PI3K   Phosphatidylinositol 3-kinase 
PPAR   Peroxisome-proliferator activated receptor 
REE   Resting energy expenditure 
SERCA  sarcoplasmic/endoplasmic reticulum calcium ATPase 
SPARC  Secreted protein acidic rich in cysteine 
SPP1   Secreted phosphoprotein 1 
STAT   Signal transducer and activator of transcription 
TFAM   Mitochondrial transcription factor A 
TGF-β  Transforming growth factor β 
TNFα   Tumor necrosis factor α 
UCP   Uncoupling protein 
VEGF   Vascular endothelial growth factor 
VLDL   Very low density lipoproteins 
  
6 
1.1 Skeletal muscle morphology and function 
 
The human body consists of around 600 muscles that contribute to approximately 
40%-50% of the total body weight. Similar to cardiac muscle, skeletal muscle is a 
striated muscle, is attached to the skeleton and thereby facilitates the movement of 
the body by applying force to bones and joints. Skeletal muscle is composed of 
myofibers that are formed by the fusion of individual myoblasts during a process 
called myogenesis. Muscle plasticity, for example the adaptation to exercise, is 
facilitated by a switch between oxidative, slow-twitch and glycolytic, fast-twitch 
muscle fibers [1]. The former are characterized by a high mitochondrial number, rich 
capillary supply, slow twitch frequency and high resistance against fatigue. The 
ample vascularization and the abundance of heme-containing proteins confer a red 
color to muscle beds with a high proportion of oxidative fibers. On the other hand, low 
mitochondrial number, fast twitch contraction kinetics, high peak force and low 
endurance are the functional hallmarks of glycolytic muscle fibers. Muscle beds 
consisting of glycolytic fibers appear more whitish in color. In rodents, type I and type 
IIa fibers are considered oxidative while type IIx and type IIb are more glycolytic. In 
humans, the spectrum of muscle fiber types is restricted to type I, IIa and IIx as well 
as hybrid fibers [2]. 
Myofibrils are composed of actin and myosin filaments arranged in sequentially 
repeated units called sarcomeres, the basic functional units of a muscle fiber that 
enables the muscle to contract. Skeletal muscle cells are the only voluntary type of 
muscle cells in contrast to cardiac muscle, smooth muscle and myoepithelial cells. 
Skeletal muscle cells are innervated by motor neurons and action potentials are 
exclusively initiated by the neurotransmitter acetylcholine in this context. Once a 
muscle cell is sufficiently depolarized, the sarcoplasmic reticulum releases calcium in 
a ryanodine receptor-dependent manner. Calcium subsequently binds to the troponin 
C subunit of the troponin complex. Troponin and tropomyosin are two important 
regulatory proteins, which are associated with actin to prevent interaction with myosin 
in the rested state. Calcium-bound troponin C then undergoes a conformational 
change that leads to an allosteric modulation of tropomyosin, which subsequently 
allows myosin to bind to actin. ATP-dependent cross bridging between myosin and 
actin then leads to a shortening of the muscle. Finally, calcium is pumped back into 
the sarcoplasmic reticulum by sarcoplasmic/endoplasmic reticulum calcium ATPases 
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(SERCA) ultimately resulting in muscle fiber relaxation. 
It is important to note that muscle function is not limited to the generation of power, 
locomotion, posture and breathing. In fact, shivering skeletal muscle is the most 
important organ for the maintenance of body temperature besides non-shivering 
thermogenesis by brown adipose tissue. Furthermore, skeletal muscle is one of the 
largest energy stores with substantial amounts of triglycerides and glycogen, in 
particular in trained subjects. In addition, anaerobic glycolysis and breakdown of 
skeletal muscle tissue during starvation releases lactate and amino acids, 
respectively, some of which subsequently are utilized to fuel hepatic (mainly alanine 
and lactate) and renal (mainly glutamine) gluconeogenesis. Thus, skeletal muscle 
has long been known to be capable of secreting factors in order to communicate with 
non-muscle tissues. However, more recently, such auto-, para- and endocrine 
mediators produced and released by skeletal muscle have been termed “myokines”, 
in analogy to the adipokines produced by adipose tissue. These secreted factors 
potentially have far-reaching effects on non-muscle tissue and thereby could provide 
a molecular link between muscle function and whole body physiology. This review will 
mainly focus on the biology of a selection of such myokines. 
 
 
1.2. Skeletal muscle plasticity  
 
Repeated contractions, for example in training, result in a pleiotropic adaptation of 
muscle cells with a dramatic remodeling of contractile and metabolic properties. 
Importantly, the diametrically opposite activation pattern in endurance and resistance 
training elicit distinct cellular consequences. For example, endurance training results 
in a switch to oxidative, slow-twitch muscle fibers while resistance exercise increases 
the proportion as well as the cross-sectional area of glycolytic muscle fibers. 
Surprisingly, the molecular mediators of these adaptations are only poorly 
understood [3]. It is clear that slow-type activation results in a more continuous 
elevation of intracellular calcium with low amplitude whereas these transients are 
characterized by more intermittent spikes with a high amplitude in glycolytic fibers in 
resistance training [4]. Nevertheless, it is unclear how the distinct calcium levels are 
interpreted to result in either a slow- or a fast-type gene program. For example, in 
both cases, the intracellular increase in calcium activates the catalytic subunit of the 
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phosphatase calcineurin A (CnA) and members of the calcium/calmodulin-dependent 
protein kinase family (CaMK) leading to a change in the phosphorylation status of 
different transcription factors and coactivators. These transcription factors include the 
cyclic-AMP-responsive-element-binding protein (CREB), myocyte-enhancer factor 2C 
(MEF2C) and MEF2D, and members of the nuclear factor of activated T cells (NFAT) 
family. In resistance-trained muscle, growth factor signaling, in particular that initiated 
by the insulin-like growth factor 1 (IGF-1), seems to be an important modifier of the 
ensuing muscle cell remodeling. In endurance-trained muscle, MEF2C/2D and NFAT 
regulate the gene expression of slow-type genes. In addition, CREB, MEF2C/2D and 
NFAT control the transcriptional rate of the peroxisome-proliferator activated receptor 
γ coactivator 1α (PGC-1α) [5]. This transcriptional coactivator constitutes a regulatory 
nexus in the adaptation of skeletal muscle to endurance training [6, 7]. Accordingly, in 
addition to the regulation by calcium signaling, PGC-1α gene expression and 
posttranslational modifications are affected by every major signaling pathway that is 
activated in a contracting muscle fiber (Fig. 1). In turn, PGC-1α coordinates the entire 
program of endurance training adaptation in skeletal muscle. For example, PGC-1α 
is recruited to more than 7500 distinct sites in the mouse genome and induces and 
inhibits the transcription of around 984 and 727 genes, respectively, in muscle cells 
[8]. Such a complex transcriptional response is enabled by a specific interaction with 
a high number of transcription factor binding partners and furthermore, selective 
modulation of the PGC-1α activity by additional co-regulators, e.g. competition with 
the corepressor NCoR1 for binding to the estrogen-related receptor α (ERRα) [9] in 
the regulation of mitochondrial genes [10]. Thus, when overexpressed in muscle, 
transgenic mice exhibit a trained phenotype [11] while skeletal-muscle-specific 
knockout animals for PGC-1α suffer from a reduced endurance capacity as well as 
other signs of pathological inactivity [12, 13]. In individual exercise bouts, stabilization 
of existing PGC-1α protein by the p38 mitogen-activated protein kinase (p38 MAPK) 
[14], phosphorylation by the AMP-dependent kinase (AMPK) [15], other 
posttranslational modifications and subsequent transcriptional induction ensure a 
rapid and robust elevation of PGC-1α activity [16, 17]. Upon cessation of muscle 
contraction, the short half-life of the PGC-1α protein and a reduction in the gene 
transcription help to revert PGC-1α levels back to baseline expression within hours. 
Chronic exercise, e.g. in endurance training, promotes a shift towards a higher 
proportion of slow-type muscle fibers. Due to the fiber-type preference in PGC-1α 
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gene expression, endurance-trained muscle exhibits higher basal transcript levels of 
PGC-1α while retaining the acute induction in each exercise bout [11, 18]. Due to the 
potent effect of PGC-1α on muscle function, modulation of the levels and/or activity of 
this coactivator might provide an interesting therapeutic avenue for metabolic and 
other diseases that are linked to an inactive muscle [19, 20]. At least experimentally, 
elevation of PGC-1α and its homolog PGC-1β indeed ameliorated several different 
muscle wasting pathologies in various mouse models  of Duchenne muscular 
dystrophy [21, 22] and a mitochondrial myopathy [23]. In the context of metabolic 
diseases, the results are less clear and it seems that bona fide physical activity is 
required to synergize the effect of overexpressed PGC-1α to improve diet-induced 
insulin resistance [24, 25]. 
 
 
1.3. The broad effect of physical inactivity on health 
 
A sedentary lifestyle is defined by a lack of or irregular physical activity and is one of 
the leading causes of preventable deaths worldwide [26, 27]. For example, 
sedentariness can contribute to the development of a number of chronic diseases, 
such as type 2 diabetes [28], cardiovascular pathologies [29], obesity [30, 31], 
postmenopausal breast cancer and other tumors [32]. Furthermore, physical inactivity 
may also play a role in the development of dementia [33], depression [34] and 
neurodegenerative events [35]. 
A persistent, sterile, inflammation is one of the most obvious features of physical 
inactivity [36]. Chronic, systemic inflammation most likely promotes the development 
of insulin resistance, atherosclerosis, neurodegeneration and tumor growth [36]. 
Historically, an excess of adipose tissue, as in the context of obesity, has been 
demonstrated to secrete increased amounts of the pro-inflammatory cytokines tumor 
necrosis factor-α (TNFα), interleukin 1-β (IL-1β) and IL-6 in both rodents and humans 
[37, 38], thus, contributing substantially to the chronic systemic inflammation. More 
recently, other organs, including liver and skeletal muscle, have been discovered as 
additional sources of pro-inflammatory cytokines in pathological settings [39, 40]. For 
example, the reduced expression of PGC-1α in skeletal muscle resulting from a 
sedentary lifestyle or gene ablation results in a low-level local as well as systemic 
inflammatory response, which then elicits negative impacts on other tissues such as 
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pancreatic β cells [41]. Inversely, PGC-1α reduces the activity of the nuclear factor 
κB (NFκB), the master regulator of pro-inflammatory gene expression [42]. Thus, by 
contributing to the production of pro-inflammatory cytokines, inactive muscles in a 




1.4. Exercise and its beneficial effects on skeletal muscle and whole body 
metabolism 
 
The beneficial effects of exercise transcend improved skeletal muscle functionality. 
For example, moderate exercise has been shown to increase life span in rats [43], to 
improve neuromuscular and neurological performance in mice [44] and to lower 
hyperglycemia [45, 46], hypercholesterolemia [47] and hypertension [48]. Similarly, 
systemic responses to exercise have been observed in distal organs like heart, 
kidney, brain and liver in various animal models [44, 49-51]. Epidemiological studies 
have likewise linked an active life-style to systemic adaptations and an elongated 
health-span, thus time of life in good health, in different human cohorts [52]. 
Intriguingly, many of these effects even occur in elderly individuals that only initiate 
exercise at advanced age highlighting the high efficacy of exercise as an intervention 
for the prevention and/or treatment for various ailments. To date, the mechanisms 
that link physical activity to health remain unknown. Nevertheless, several 
hypotheses have been proposed to contribute to the beneficial effects of exercise. 
For example, the sought-after whole body adaptations to exercise could be induced 
by a general reduction in systemic inflammation since inversely, a persistent, sterile 
inflammatory state has been linked to the etiology of many chronic diseases [36, 53]. 
Thus, regular physical activity acutely increases the release of adrenaline, cortisol, 
growth hormone, prolactin and other factors with immunomodulatory effects [54]. 
Importantly however, long-term training is associated with decreased circulating 
levels of the classical stress hormones. Moreover, exercise reduces the expression 
of Toll-like receptors at the surface of monocytes that have been implicated as 
mediators of systemic inflammation [55]. Importantly, very high intensity exercise 
bouts themselves trigger systemic inflammation, a subsequent immunodepression 
and thus a higher risk for infections [56]. Muscle function, inflammation and exercise 
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are hence intrinsically linked in a complex manner [36, 40]. Therefore, not 
surprisingly, many myokines, for example interleukin 6, have also been described as 
prototypical pro-inflammatory cytokines. Induction of beneficial versus detrimental 
effects therefore seems highly context-specific and might depend on the amplitude, 





It is now firmly established that skeletal muscle tissue produces and secretes 
cytokines and other proteins, which have been named “myokines” [57]. Myokines 
subsequently exert auto-, para- and/or endocrine effects (Fig. 2). Thus, skeletal 
muscle can be classified as an endocrine organ. Since the description of the first 
members, the list of myokines has constantly been growing demonstrating that 
skeletal muscle has the capacity to express several myokines, some simultaneously, 
others in a temporally- or context-controlled manner. For most currently described 
myokines, contractile activity is the key regulatory element for expression and 
secretion. In this review we will focus on some of the classical as well as some of the 
more exotic myokines, describe their regulation in skeletal muscle and their possible 
systemic effects on distal non-muscle tissues. Furthermore, we will highlight the 
newest members of the myokine family and their potential application in combating 
metabolic diseases.  
 
 
2.2. Myostatin  
 
Myostatin (MSTN) is a member of the transforming growth factor β (TGF-β) 
superfamily that is expressed in the developing and adult skeletal muscle. The main 
function of myostatin is to negatively regulate muscle mass [58]. Evolutionarily, 
actively limiting muscle growth might have helped to prevent the build-up of energy-
consuming muscle mass beyond the needs of the current situation. Accordingly, 
myostatin null mice exhibit a massive muscle hypertrophy that is characterized by an 
increased fiber cross-sectional area as well as an elevated number of fibers. The 
hyperplasia in this animal model most likely originates from accelerated primary and 
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secondary myogenesis. Importantly, the myostatin gene is highly conserved among 
different vertebrate species. For example, myostatin mutations in some domestic 
breeds of cattle including the Piedmontese, Belgian Blue and Marchigiana result in a 
so called double-muscling phenotype and hence pronounced muscle hypertrophy 
[59-61]. Similar double muscling phenotypes have been observed in sheep and the 
whipped dog breed that leads to increased muscle mass and racing performance in 
the latter [62]. Finally, a mutation in the myostatin gene has also been associated 
with muscle hypertrophy in a male child with extraordinary muscularity and several 
relatives with self-reported unusual strength [63]. 
In addition to the hypertrophic muscle phenotype, myostatin null mice show reduced 
total and intramuscular body fat compared to wild-type animals [58, 64]. An increase 
in muscle mass leads to increased resting energy expenditure (REE), which in turn 
could account for the reduction in fat mass in myostatin knockout animals [58]. 
Accordingly, circulating levels of leptin, the “satiety hormone”, are reduced in these 
mice [64, 65] hence suggesting that despite decreased leptin secretion, myostatin 
null mice are protected from the counter-regulatory consequence of leptin signaling 
on energy expenditure. Moreover, myostatin might directly influence the cellular 
physiology of adipocytes even though the results are conflicting. For example, 
myostatin inhibits the differentiation of 3T3-L1 preadipocytes and reduces the 
expression of several adipogenic markers and transcription factors such as the 
peroxisome proliferator-activated receptor γ (PPARγ), CCAAT-enhancer-binding 
protein α (C/EBPα), adipocyte protein 2 (aP2) and leptin [66, 67]. In contrast, in a 
multipotent mesenchymal cell line (C3H10T1/2), myostatin promotes adipogenesis, 
which would be more in line with the reduced adiposity in myostatin knockout animals 
[68, 69]. Inversely however, pharmacological administration of myostatin in vitro and 
in vivo is not able to increase lipolysis and to reduce fat mass [67] suggesting that the 
reduction in body fat in myostatin null animals is indeed due to the increased muscle 
mass and only to a lesser extent to direct effects on adipose tissue. 
Even though not called a myokine at the time of its discovery, myostatin is one of the 
first members of this class of proteins. However, since both aerobic exercise [70-73] 
and strength training [74-78] in animals and humans significantly reduce expression 
in skeletal muscle, myostatin is more like an “inverse” myokine compared to most 
other family members that are elevated by exercise. In addition to transcript levels, 






In contrast to myostatin, decorin is a more recently discovered myokine that is 
elevated in mice and humans after acute and chronic resistance exercise [80]. 
Overexpression of decorin in transgenic models resulted in a pro-hypertrophic gene 
program, for example elevated Mighty, MyoD and follistatin gene expression. Decorin 
seems to act in a paracrine manner by directly binding to and thereby inhibiting the 
action of myostatin [80]. Therefore, decorin can act as a myokine that antagonizes 
the effects of another myokine, in this case myostatin, and in addition also neutralize 
myostatin of non-muscle origin, for example myostatin released from tumor cells in 





Interleukin-6 (IL-6) has originally been classified as a prototypical pro-inflammatory 
cytokine while later, anti-inflammatory properties have also been described [82]. 
Besides the production of IL-6 in activated immune cells, the systemic elevation of IL-
6 in patients with metabolic diseases has contributed to the link of IL-6 and 
inflammation. Moreover, overexpression of IL-6 in transgenic mice results in reduced 
body mass and impaired insulin-stimulated glucose uptake by skeletal muscle [83]. 
Thus, IL-6 has been proposed as one of the pro-inflammatory factors that promote 
the development of peripheral insulin resistance. In stark contrast however, exercise-
induced elevation of IL-6 plasma levels lead to increased circulating levels of several 
potent anti-inflammatory cytokines such as IL-1ra and IL-10, suggesting that IL-6 may 
also have anti-inflammatory properties [84, 85]. 
IL-6 is produced by a number of cells in vivo including stimulated 
monocytes/macrophages, fibroblasts and vascular endothelial cells [86]. Skeletal 
muscle fibers also express and release IL-6 during and after exercise [86-89]. IL-6 
production is likewise boosted in connective tissue, the brain and adipose tissue 
post-exercise [90]. Exercise-induced plasma IL-6 concentrations peak at the end or 
shortly after cessation of an acute exercise bout and quickly return to pre-exercise 
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levels [91]. IL-6 mRNA levels are generally induced in contracting skeletal muscle 
[87, 92]: however, exercise further enhances the transcriptional rate of IL-6 if muscle 
glycogen stores are low [93]. As IL-6 is a classical inflammatory cytokine, it was 
initially thought that exercise-induced IL-6 is released in response to muscle injury. 
However, several lines of evidence indicate that substantial amounts of IL-6 are 
produced independent of muscle injury [85, 87, 94].  
When IL-6 was discovered and classified as one of the founding members of the 
myokine class of proteins, Pedersen et al. suggested IL-6 to possess some of the 
characteristics of a true “exercise factor”, which exerts is effects both locally within 
the muscle bed and peripherally on distal organs in an endocrine-like fashion [95]. In 
skeletal muscle, IL-6 signals through a gp130Rβ/IL-6Rα homodimer leading to the 
activation of AMPK and/or phosphatidylinositol 3-kinase (PI3K) and, subsequently, to 
an increase in glucose uptake and fatty acid oxidation [96, 97]. Similarly, enhanced 
AMPK activity upon IL-6 signaling has also been reported in adipose tissue [98]. 
Furthermore, IL-6 has been suggested to stimulate hepatic glycogenolysis, 
gluconeogenesis and glucose release [99]. Furthermore, IL-6 stimulates the secretion 
of glucagon-like peptide-1 (GLP-1), which results in an enhanced secretion of insulin 
from intestinal L-cells and pancreatic α-cells [100]. 
Thus, IL-6 release in response to exercise seems to have pleiotropic effects by 
increasing glucose uptake and fatty acid oxidation locally in skeletal muscle and 
enhancing insulin secretion, which further increases glucose uptake into muscle cells. 
At the same time hepatic glucose output [99] and fatty acid release from adipose 






Interleukin-8 (IL-8) is a chemokine that attracts primary neutrophils [102]. In addition, 
IL-8 associates with the CXC receptor 2 (CXCR2) and thereby promotes 
angiogenesis [103-105]. IL-8 mRNA levels in skeletal muscle are elevated after 
exercise [106-108] and IL-8 plasma levels were found to be increased after eccentric 
muscle contractions [106, 109-112]. Curiously, systemic IL-8 plasma concentrations 
are unchanged following concentric exercise [106-108, 113], suggesting that the 
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main part of the systemic increase in IL-8 after eccentric exercise, which is 
associated with a higher degree of fiber damage compared to concentric 
contractions, may account for a general inflammatory response [95]. Nevertheless, a 
small and transient net release of IL-8 has been reported across a concentrically 
exercising limb [107], indicating that muscle-derived IL-8 still acts locally in an auto- 
and/or paracrine manner while not substantially contributing to the systemic IL-8 
plasma concentration in this context. 
Even though the physiological function of IL-8 on skeletal muscle is still unknown, the 
association with CXCR2 suggests at least a role in promoting exercise-induced 
neovascularization of muscle tissue. This assumption is further supported by the fact 
that CXCR2 mRNA and protein levels are induced upon concentric exercise in the 





Interleukin-15 (IL-15) is a pro-inflammatory cytokine with structural similarities to IL-2 
and regulates T and natural killer cell activation and proliferation [115, 116]. IL-15 
binds and signals through the IL15Rαβγ complex, which is upstream of the Janus 
kinases 1 and 3 (JAK1, 3) and signal transducer and activator of transcription-3 and 5 
(STAT3, 5) [117, 118]. Expression of IL-15 mRNA has been detected in several 
human tissues including heart, lung, liver and kidney, but most abundantly in 
placenta and skeletal muscle. Similarly, peripheral blood mononuclear, epithelial and 
fibroblast cells seem to express significant levels of IL-15 [116]. 
Originally, IL-15 has been described as an anabolic factor in skeletal muscle. For 
example, even one bout of resistance training accordingly elevated IL-15 mRNA 
expression in human skeletal muscle [119]. Furthermore, IL-15 stimulates the 
production of contractile proteins [120] and overexpression of IL-15 in vitro results in 
muscle cell hypertrophy [121]. Moreover, IL-15 treatment of tumor-bearing rats 
antagonizes cancer cachexia [122] demonstrating the therapeutic potential in muscle 
wasting diseases. More detailed analyses of these in vivo studies however provided 
a different picture [123]: for example, administration of IL-15 did not affect muscle 
mass in the healthy control animals [122]. Transgenic overexpression of IL-15 [121] 
and muscle-specific ablation of the IL-15 receptor α [124] strongly implicated IL-15 in 
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promoting an oxidative, high-endurance muscle phenotype. Accordingly, IL-15 
promotes skeletal muscle glucose uptake and fatty acid oxidation [125, 126]. 
Moreover, twelve weeks of endurance training resulted in an elevation of IL-15 
protein in skeletal muscle of human volunteers, even though mRNA expression and 
IL-15 plasma levels remained unchanged [127]. Thus, future experiments will have to 
elucidate whether the assignment of IL-15 as an anabolic factor has been spurious 
and based on in vitro-specific effects or if a dual role for IL-15 in both resistance as 
well as endurance training adaptation could be possible in a context-specific manner. 
Interestingly, diametrically opposite to the postulated anabolic effects on skeletal 
muscle, IL-15 inversely shrinks adipose tissue mass. In humans, a negative 
correlation between IL-15 plasma levels and trunk fat mass has been demonstrated 
and likewise, IL-15 overexpression in mouse skeletal muscle decreases visceral fat 
mass [128]. Besides the strong IL-15-dependent remodeling of skeletal muscle, this 
reduction in fat mass might also be associated with the effects of IL-15 on liver 
metabolism. For example, chronic administration of IL-15 decreases hepatic 
lipogenesis [129] and, at the same time, boosts hepatic fatty acid oxidation [126]. 
Together, these two effects potentially reduce the export of very low density 
lipoproteins (VLDL). Accordingly, IL-15 treatment of animals diminishes circulating 
VLDL levels in comparison to non-treated control animals [130]. 
Finally, IL-15 administration decreases brown adipose tissue (BAT) mass in rats. At 
the same time however, the transcript levels of the uncoupling proteins 1 and 3 
(UCP1, 3), lipid-related transcription factors and other proteins involved in membrane 
and mitochondrial transport and fatty acid oxidation are induced [131] and thereby, 
BAT thermogenesis and fatty acid oxidation are boosted. 
 
 
2.7. Brain-derived neurotrophic factor 
 
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, is 
strongly expressed in the brain [132] and to a lesser extent in skeletal muscle [133]. 
In the CNS, BDNF regulates neuronal development and modulates synaptic 
plasticity, playing a role in the regulation of survival, growth and maintenance of 
neurons [134, 135]. Furthermore, hypothalamic BDNF has been identified as a key 
factor in the control of body mass and energy homeostasis [136]. BDNF also 
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influences learning and memory [137] and brain samples of patients with Alzheimer’s 
disease exhibit reduced expression of BDNF [138]. Similarly, BDNF serum levels of 
patients with depression, obesity and type 2 diabetes are decreased [139, 140]. 
Inversely, exercise increases circulating BDNF levels in humans [141] and recent 
studies suggest that the brain contributes 70-80% of the circulating BDNF in this 
context [142]. BDNF mRNA and protein levels are also increased in skeletal muscle 
in response to exercise and contribute to enhanced fat oxidation by activating AMPK 
[133]. However, muscle-derived BDNF seems not to be released into the circulation 
in significant amounts indicating that BDNF primarily acts in an auto- and/or paracrine 
manner. Accordingly, besides the effects on metabolic properties, the main 
consequences of modulation of muscle BDNF extend to myogenesis, satellite cell 
activation and skeletal muscle regeneration [143, 144]. Other members of the 
neurotrophin factor family, in particular neurotrophin-3 (NT-3) and NT-4/5, have also 
been found in skeletal muscle tissue [145, 146]. However, even though a potential 
role of NT-3 and NT-4/5 in the repair of peripheral nerve injury has been suggested 
[145], the regulation and function of NT-3 and NT-4/5 in muscle remains unclear. 
 
 
2.8. Ciliary neurotrophic factor 
 
Like BDNF, ciliary neurotrophic factor (CNTF) is also a member of the neurotrophin 
family with important functions in the regulation of neural survival, development, 
function and plasticity [132]. Surprisingly, CNTF is also involved in the regulation of 
osteoblasts. For example, female CNTF-deficient mice exhibit increased bone mass 
and osteoblast activity compared to control animals. Moreover, CNTF decreases the 
mineralization and production of the osteoblast differentiation factor osterix in 
osteoblasts in vitro [147].  
Recently, CNTF has been identified as a myokine that negatively regulates 
osteoblast gene expression together with the soluble CNTF receptor [148]. 
Therefore, muscle-derived CNTF could be a molecular link that underlies reduced 
bone formation in inactive individuals and therefore might contribute to osteoporosis 
boosted by a sedentary life-style. Inversely however, CNTF production in inactive or 
resting muscle fibers may prevent heterotopic ossification of the muscle or regulate 




2.9. Vascular endothelial growth factor and secreted phosphoprotein 1 
 
Vascular endothelial growth factor (VEGF) is a mitogen with specificity for vascular 
endothelial cells [149] and is a crucial regulator of embryonic vascular development 
(vasculogenesis) as well as blood vessel formation (angiogenesis). In fact, VEGF is 
most likely the most important pro-angiogenic growth factor in most tissues including 
skeletal muscle [150]. VEGF mRNA and protein levels are upregulated in skeletal 
muscle following an acute bout of exercise [151-153]. Furthermore, interstitial VEGF 
levels likewise increase markedly after exercise [152, 154] suggesting that VEGF is 
indeed secreted from contracting skeletal muscle fibers. This is further supported by 
a study showing that electrostimulation of cultured muscle cells leads to the secretion 
of VEGF into the culture medium [150]. Thus, skeletal muscle controls its own 
capillary supply be secreting VEGF into the extracellular space where VEGF acts on 
the vascular endothelial cells to increase blood vessel formation, and thus ultimately 
improve oxygen and energy substrate transport to the exercising muscle. In many 
different cell types, VEGF activity is determined by the hypoxia inducible factor 1α 
(HIF-1α), one of the main regulators of VEGF gene transcription, in addition to a 
strong regulation at the post-transcriptional level [155]. In contracting skeletal muscle 
tissue, an alternative, HIF-1α-independent regulation of VEGF transcription has been 
discovered centered on PGC-1α, in functional interaction with ERRα [156] and the 
activator protein-1 (AP-1) [8]. Interestingly, VEGF-induction by PGC-1α is further 
coordinated with a PGC-1α-dependent elevation of the secreted phosphoprotein 1 
(SPP1). SPP1, a new myokine, that helps to orchestrate physiological angiogenesis 
by stimulating macrophages and in turn, activating endothelial cells, pericytes and 
smooth muscle cells [157]. 
 
 
2.10. Fibroblast growth factor 21 
 
Fibroblast growth factor 21 (FGF21) belongs to the FGF super family with major 
functions in modulating cell proliferation, growth and differentiation as well as 
metabolism [158, 159]. FGF21 is predominantly expressed and secreted by the liver 
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[160] but also by adipose tissue, pancreas and skeletal muscle [161]. The liver mainly 
secretes FGF21 in response to fasting [162] while BAT secrets FGF21 upon 
noradrenergic stimulation [163]. In the liver, FGF21 induces the expression of PGC-
1α that in turn increases fatty acid oxidation, TCA cycle flux and gluconeogenesis 
[164].  
In adipose tissue, FGF21 stimulates glucose uptake and transgenic overexpression 
of FGF21 protects mice from diet-induced obesity. Furthermore, FGF21 
administration to diabetic rodents lowers blood glucose and triglyceride levels 
demonstrating its potential therapeutic application [165].   
A recent study suggests that FGF21 is an insulin-regulated myokine that is 
expressed in skeletal muscle in response to insulin stimulation [166]. Moreover, cold-
induced FGF-21 in muscle could contribute to an activation of thermogenesis [167]. 
FGF21 expression in skeletal muscle is also increased in a mouse model for a 
mitochondrial myopathy and the ensuing FGF21 elevation in the circulation promotes 
a starvation-like response in this disease context [168]. These results suggest that 




2.11. Irisin, meterorin-like and β-aminoisobutyric acid 
 
Since PGC-1α is a crucial regulator of skeletal muscle plasticity after exercise [16] 
and accordingly, PGC-1α levels often correlate with those of myokines [169], PGC-1α 
gain- and loss-of-function models have been used to identify novel myokines. For 
example, screening of muscle cells that overexpress PGC-1α in three recent studies 
led to the identification of three new PGC-1α-dependent myokines, irisin [170], 
BAIBA [171] and meteorin-like [172]. Intriguingly, all three myokines seem to be 
involved in promoting beige fat thermogenesis.  
2.11.1. Irisin. Irisin is cleaved off from FNDC5, a membrane-bound protein in skeletal 
muscle that is induced by exercise and muscle shivering [167]. Irisin exerts its action 
on white adipose tissue cells to stimulate UCP-1 expression and other brown fat-like 
genes thereby inducing browning and thermogenesis of white adipose tissue. 
Collectively, these effects lead to an increase in energy expenditure and result in an 
improvement of adiposity and glucose homeostasis [170]. Besides skeletal muscle, 
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FNDC5 is also expressed in the brain [173, 174]. By elevating systemic irisin levels, 
endurance exercise induces FNDC5 expression in the hippocampus in a PGC-1α-
dependent manner, which then leads to increased hippocampal BDNF expression 
and ultimately neurogenesis in this brain region. Accordingly, peripheral delivery of 
FNDC5 via adenoviral vectors is sufficient to induce BDNF expression in the brain 
[175]. Therefore, FNDC5/irisin might be the molecular mediator of exercise-induced 
neurogenesis in a direct skeletal muscle-brain cross-talk. 
In addition to these endocrine effects, irisin also positively regulates muscle 
metabolism. Myocytes treated with irisin in vitro express higher levels of PGC-1α, 
nuclear respiratory factor 1 (NRF-1), mitochondrial transcription factor A (TFAM), 
glucose transporter 4 (GLUT4), UCP3, and irisin implying a positive autoregulatory 
loop between PGC-1α and FNDC5 [176]. Thereby, energy expenditure and oxidative 
metabolism in muscle cells is elevated by irisin. Importantly, while data in mice are 
robust, the regulation and function of irisin in humans is currently under debate. 
Future studies will have to show why irisin is only induced in some, but not all 
exercise cohorts. As with other factors, irisin regulation could depend on the specific 
training protocol (e.g. intensity, endurance vs. resistance, acute vs. chronic, time of 
blood sampling after exercise), age, gender, ethnicity, fitness and other variables. 
Second, the presence of circulating irisin in humans will have to be further 
investigated since the human FNDC5 gene lacks a functional start codon and 
detection of the protein has been questioned due to supposed suboptimal antibody 
specificity [177]. Notably however, 2-4% of eukaryotic genes contain an atypical start 
codon and nevertheless can be transcribed [178, 179]. Moreover, circulating human 
irisin has been described in several studies using different antibodies and assays 
such as highly sensitive mass spectroscopy [167]. 
2.11.2. Meteorin-like. Meteorin-like (Metrnl) is a hormone that has been identified as 
a myokine which is induced in skeletal muscle upon exercise and in white adipose 
tissue upon cold exposure [172]. Interestingly, in contrast to FNDC5/irisin, Metrnl 
primarily is dependent on the PGC-1α isoform 4 (PGC-1α4). PGC-1α4 is a splice 
variant of PGC-1α with a very distinct gene regulation pattern [74]. In contrast to the 
other known PGC-1α variants that primarily promote an oxidative, high endurance 
muscle phenotype, PGC-1α4 is induced by resistant training and enhances muscle 
hypertrophy and strength [74]. Nevertheless, even though the regulation of irisin and 
Metrnl is specific, Metrnl also increases whole body energy expenditure and 
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improves glucose tolerance in obese/diabetic mice by indirectly activating the 
browning gene program in white adipose tissue via stimulation of an eosinophil-
macrophage signaling cascade to ultimately activate a pro-thermogenic program 
[172].  
2.11.3. BAIBA. BAIBA (β-aminoisobutyric acid) is an atypical myokine inasmuch 
BAIBA is not a cytokine-like molecule or even a protein. Nevertheless, BAIBA 
behaves clearly in a myokine-specific manner by being secreted from PGC-1α-
expressing myocytes and subsequently activating the thermogenic program and 
beigeing of white adipose tissue [180]. In a similar endocrine fashion, BAIBA 
increases β-oxidation in hepatocytes both in vitro and in vivo by activating the 
transcription factor PPARα. In mice and in humans in vivo, circulating BAIBA levels 
increase with exercise and are inversely correlated with cardiometabolic risk factors 
in humans. Thus, exercise-induced circulating BAIBA has been suggested to protect 
from metabolic diseases [171]. 
 
Strikingly, all of these three newly identified PGC-1α-dependent myokines exert a 
strong endocrine effect on white adipose tissue by promoting a 
browning/thermogenic response and thereby increasing energy expenditure. The 
subsequent improvement of adiposity and whole body metabolism is of obvious 
interest for the treatment of obesity and obesity-associated diseases like type 2 
diabetes. Moreover, increased adrenergic signaling during exercise can at least 
mechanistically be linked to a browning effect [181]. Nevertheless however, browning 
of white adipose tissue and, as a consequence, elevation of energy expenditure in 
the context of exercise raises interesting conceptual questions. With a degree of 
efficiency of around 15-25%, exercising muscle already produces significant heat that 
has to be dissipated by vasodilation and sweating in order to sustain prolonged 
contractions. It thus seems counterintuitive for skeletal muscle to directly initiate a 
myokine-dependent program that results in even further heat production in beige 
adipose tissue and as a consequence, usage of energy substrates that should 
optimally be available for muscle, and not adipose tissue, both for contractions as 
well as post-exercise refueling of energy stores. In the original manuscript, the 
authors speculated that such a program could be an evolutionary consequence of 
shivering thermogenesis that became increasingly important in higher organisms 
[170]. Indeed, recent work identified irisin and FGF-21 as cold-induced endocrine 
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activators of thermogenesis in humans [167]. In fact, irisin secretion closely 
correlated with shivering intensity further supporting the hypothesis of a specification 
of skeletal muscle to sustain and coordinate both shivering in muscle as well as non-
shivering thermogenesis in beige and brown adipocytes [182]. 
 
 
2.12. Anti-tumorigenic myokines: SPARC and OSM 
 
An active life-style is not only associated with a decreased risk for the development of 
metabolic diseases such as cardiovascular pathologies and type 2 diabetes, different 
studies also imply a possible link between physical activity and certain types of 
cancer [27, 183]. For example, the World Cancer Research Fund proposed that 
exercise reduces the risk for developing breast and colon cancer by 25-30% [184]. 
There is a growing list of potential mechanisms how exercise may exhibit anti-
tumorigenic effects, even though the molecular pathways are still largely unknown. 
Recently, two myokines have been identified, secreted protein acidic and rich in 
cysteine (SPARC) [185] and oncostatin-M (OSM) [186], which suppress tumor 
formation in the colon and inhibit mammary cancer cell growth, respectively. Both 
myokines inhibit proliferation and induce apoptosis of cancer cells. While such effects 
are of obvious therapeutic importance, the physiological roles of these two myokines 
remain unclear. Future studies might elucidate whether SPARC and OSM likewise 
regulate cell proliferation and apoptosis after being produced and secreted in 




3.1 Training, myokines and “exercise factors” 
 
As described in the individual sections above, a clear regulatory and functional role 
linked to exercise has been found for some myokines. For example, IL-6 expression 
closely correlates with muscle contraction [91]. In turn, e.g. by promoting hepatic 
gluconeogenesis [99] and lipolysis in adipose tissue [98], IL-6 subsequently 
contributes to an adequate supply of energy substrates for the contracting muscle by 
affecting distal organs. Accordingly, IL-6 has been declared to constitute a bona fide 
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“exercise factor” [95]. For other myokines, such a direct link to exercise is lacking; in 
some cases, the physiological relevance of the consequences of myokine action in 
the context of exercise remains enigmatic (e.g. the increase in brown fat-associated 
thermogenesis). Accordingly, the definition of “exercise factors” as a subgroup of 
myokines has been proposed based on the following criteria [187]: “exercise factors” 
are regulated by exercise and subsequently released into the circulation in order to 
exert distal effects. Non-exercise factor myokines are not necessarily controlled by 
muscle contraction and might not have a systemic function. Importantly, myokines do 
not have to be exclusively produced by skeletal muscle – indeed, the vast majority of 
the currently described myokines are also found in other tissues [187]. Finally, 
“exercise factors” can furthermore be stratified as acute or chronic based on their 
secretion pattern since skeletal muscle will elicit dramatically different phenotypic 
consequences in distal tissues following an acute bout or long-term training [188]. 
Based on these criteria and the presence of a complete chain of evidence, Catoire 
and Kersten proposed IL-6, SPARC, Angptl4, CX3CL1 and CCL2 as myokines with 
the highest potential to constitute “exercise factors” in humans [187]. Obviously, more 





The discovery of myokines has opened a vast new and exciting field in the study of 
muscle, and, in particular, exercise physiology. Even now, members of the myokine 
group of signaling molecules cover a whole range of auto-, para- and endocrine 
effects. Importantly, different in vitro and in vivo approaches identify novel potential 
myokines at a breath-taking pace. For example, recent secretome analyses of 
cultured human muscle cells, with or without electrical stimulation, revealed over 50 
novel candidate proteins [189-191]. Obviously, a myokine function of these proteins 
remains to be tested in murine and human in vivo models. Likewise however, a 
complete chain-of-evidence of the skeletal muscle cell origin of many myokines 
described in vivo is still missing. Therefore, future studies aimed at the identification 
and characterization of novel myokines will optimally combine in vitro and in vivo 
experiments. Next, the current studies aimed at the identification of exercise-induced 
myokines might be combined with a “myokine-ome” analysis of the inactive, 
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sedentary muscle. So far, only myostatin or CNTF might fit that description – 
however, it would be surprising if myostatin and CNTF were the only “sedentary” 
myokines. Finally, non-protein myokines such as BAIBA might gain further relevance 
in the future to explain systemic plasticity initiated by skeletal muscle. Intriguingly, 
muscle-mediated conversion of kynurenine to kynurenic acid, a metabolite unable to 
cross the blood brain barrier, could underlie the beneficial effect of physical activity 
on stress-induced depression and thereby provide another example for a metabolite 
link between muscle and brain [192]. In any case however, myokines not only provide 
a molecular explanation for the extensive cross-talk between muscle and other 
tissues in our body, but also reveal novel therapeutic avenues for the treatment of a 
myriad of chronic diseases that are associated with a sedentary life-style. Thus, the 
study of myokines will remain an extremely interesting research topic for our 
understanding of basic as well as translational aspects of skeletal muscle physiology 
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Fig. 1. Central role of PGC-1α in the regulation of skeletal muscle cell plasticity. 
Every major signaling pathway that is activated in a contracting muscle fiber during 
and after endurance training converges on PGC-1α by modulating PGC-1α gene 
expression and/or post-translational modifications of the PGC-1α protein. As a 
consequence, PGC-1α in turn coordinates the transcriptional network that controls 
the biological program of exercise-induced muscle remodeling.  
 
Fig. 2. Auto-, para- and endocrine effects of myokines. Selected examples of the 
physiological consequences of the production and release of myokines on skeletal 
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